Drug intelligence / Profile preview

YH14659

Development stage: Phase 1
Lead developer: Yuhan
Modality: Small Molecules
Administration: Oral

Overview

YH14659 is an oral fixed-dose capsule combination of **clopidogrel** and **aspirin** developed by Yuhan for dual antiplatelet therapy. Clopidogrel is a prodrug whose active metabolite irreversibly inhibits the platelet P2Y12 adenosine diphosphate receptor, while aspirin irreversibly inhibits cyclooxygenase-1 in platelets, reducing thromboxane A2 production. The combination was evaluated in Phase 1 crossover pharmacokinetic studies in healthy male volunteers against separately administered clopidogrel and aspirin, with acute coronary syndrome listed in the trial records.

Targets

P2Y12 (Purinergic P2Y12 receptor)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on YH14659.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YH14659.

Explore the full profile